NCT04857164View on ClinicalTrials.gov

Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

August 20, 2023

Study Completion Date

January 1, 2026

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Pembrolizumab combined with Chemotherapy

Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer Chemotherapy regimen is selected by the investigator immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.

Trial Locations (1)

100021

RECRUITING

National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Yuankai Shi

OTHER